107 related articles for article (PubMed ID: 31809328)
1. Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status: A Systematic Review and Meta-Analysis of Overall Survival Data.
Butaney M; Satkunasivam R; Goldberg H; Freedland SJ; Patel SP; Hamid O; Pal SK; Klaassen Z; Wallis CJD
Am J Clin Oncol; 2020 Mar; 43(3):193-202. PubMed ID: 31809328
[TBL] [Abstract][Full Text] [Related]
2. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
3. Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies: A Systematic Review and Meta-Analysis.
Wallis CJD; Satkunasivam R; Butaney M; Khan UA; Goldberg HA; Freedland SJ; Patel SP; Hamid O; Pal SK; Klaassen Z
Am J Clin Oncol; 2019 Sep; 42(9):711-716. PubMed ID: 31335350
[TBL] [Abstract][Full Text] [Related]
4. Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Hu X; Liu Y; He Y; Wang Z; Zhang H; Yang W; Lu J
J Oncol; 2022; 2022():3601942. PubMed ID: 35646119
[TBL] [Abstract][Full Text] [Related]
5. Patient performance status and cancer immunotherapy efficacy: a meta-analysis.
Bersanelli M; Brighenti M; Buti S; Barni S; Petrelli F
Med Oncol; 2018 Aug; 35(10):132. PubMed ID: 30128793
[TBL] [Abstract][Full Text] [Related]
6. Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.
Wallis CJD; Butaney M; Satkunasivam R; Freedland SJ; Patel SP; Hamid O; Pal SK; Klaassen Z
JAMA Oncol; 2019 Apr; 5(4):529-536. PubMed ID: 30605213
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
[TBL] [Abstract][Full Text] [Related]
8. Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Yan X; Tian X; Wu Z; Han W
Front Oncol; 2020; 10():1671. PubMed ID: 33072551
[No Abstract] [Full Text] [Related]
9. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
Conforti F; Pala L; Bagnardi V; Viale G; De Pas T; Pagan E; Pennacchioli E; Cocorocchio E; Ferrucci PF; De Marinis F; Gelber RD; Goldhirsch A
J Natl Cancer Inst; 2019 Aug; 111(8):772-781. PubMed ID: 31106827
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
12. Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis.
Ninomiya K; Oze I; Kato Y; Kubo T; Ichihara E; Rai K; Ohashi K; Kozuki T; Tabata M; Maeda Y; Kiura K; Hotta K
Acta Oncol; 2020 Mar; 59(3):249-256. PubMed ID: 31782328
[No Abstract] [Full Text] [Related]
13. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L
Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142
[TBL] [Abstract][Full Text] [Related]
15. Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data.
Wallis CJD; Lawson K; Butaney M; Satkunasivam R; Parikh J; Freedland SJ; Patel SP; Hamid O; Pal SK; Klaassen Z
Jpn J Clin Oncol; 2020 Jul; 50(7):800-809. PubMed ID: 32083295
[TBL] [Abstract][Full Text] [Related]
16. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Steuer CE; Wu C; Lawson DH; Kudchadkar R; Master VA; El-Rayes B; Ramalingam SS; Owonikoko TK; Harvey RD
BMC Cancer; 2019 Aug; 19(1):857. PubMed ID: 31464611
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials.
Raphael J; Chan K; Karim S; Kerbel R; Lam H; Santos KD; Saluja R; Verma S
Clin Lung Cancer; 2017 Jul; 18(4):345-353.e5. PubMed ID: 28188101
[TBL] [Abstract][Full Text] [Related]
18. Survival and disease-free benefits with mastectomy versus breast conservation therapy for early breast cancer: a meta-analysis.
Chen Y; Jiang L; Gao B; Cheng ZY; Jin J; Yang KH
Breast Cancer Res Treat; 2016 Jun; 157(3):517-25. PubMed ID: 27246814
[TBL] [Abstract][Full Text] [Related]
19. The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis.
Ciccarese C; Iacovelli R; Bria E; Palazzo A; Maiorano BA; Mosillo C; Carbone C; Piro G; Tortora G
J Immunother; 2020 Apr; 43(3):95-103. PubMed ID: 32080018
[TBL] [Abstract][Full Text] [Related]
20. Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis.
Ciccarese C; Iacovelli R; Bria E; Mosillo C; Bimbatti D; Fantinel E; Bisogno I; Brunelli M; Tortora G
Semin Oncol; 2019 Feb; 46(1):65-72. PubMed ID: 30665685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
